Udai Banerji, MD on Phase 1 Study of a RAF-MEK Inhibitor CH5126766 @udai_banerji

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers.

Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator